{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:23:24Z","timestamp":1777389804926,"version":"3.51.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"crossref","award":["14-2025-0001"],"award-info":[{"award-number":["14-2025-0001"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["RS-2025-25454860"],"award-info":[{"award-number":["RS-2025-25454860"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss in the elderly. Although anti-vascular endothelial growth factor (VEGF) therapy has improved the visual prognosis of exudative AMD, a considerable proportion of patients still develop severe vision loss. However, real-world data on the prevalence, incidence and risk factors for visual disability among patients with exudative AMD remain limited. This study investigates the prevalence, incidence and risk factors for visual disability among patients with exudative AMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This nationwide, population-based retrospective cohort study used Korean National Health Insurance Service data from 2009 to 2023. Patients with newly diagnosed exudative AMD were identified, with a two-year washout period (2009\u20132010). Prevalence, incidence, hazard ratio (HR) for visual disability were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 147,406 patients with exudative AMD were included. The prevalence of visual disability in 2023 was 4.82% and the overall incidence rate was 12.18 per 1,000 person-years. At 8\u202fyears, the cumulative incidence probability of monocular visual disability was 4.8% (95% CI, 4.6\u20135.1), and that of binocular visual disability was 4.4% (95% CI, 4.1\u20134.7). The mean duration from exudative AMD diagnosis to visual disability was 3.3\u202f\u00b1\u202f2.6\u202fyears. The risk of visual disability increased with older age group (HR, 1.38; 95% CI, 1.35\u20131.42) and lower income level (HR, 1.06; 95% CI, 1.05\u20131.08). Female sex (HR, 1.41; 95% CI, 1.35\u20131.47), diabetic retinopathy (HR, 1.16; 95% CI, 1.08\u20131.25), glaucoma (HR, 1.10; 95% CI, 1.05\u20131.15), and severe intraocular hemorrhage requiring vitrectomy (HR, 3.14; 95% CI, 2.63\u20133.75) were also significant risk factors. A decreasing trend in visual disability incidence was observed among patients who were more recently diagnosed with exudative AMD (\u22120.25% point per year;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The burden of AMD-related visual disability remains significant, highlighting the need for strategies to improve treatment adherence and ensure equitable access to vision-preserving care. The decreasing trend of visual disability in recent years suggests the practical benefit of improved access to anti-VEGF treatment through lower drug costs and expanded insurance coverage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1766076","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:54Z","timestamp":1772688354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence, incidence and risk factors of visual disability in patients with exudative age-related macular degeneration: a nationwide population-based study in Korea"],"prefix":"10.3389","volume":"13","author":[{"given":"Min Seok","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital","place":["Seongnam, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonghee","family":"Nam","sequence":"additional","affiliation":[{"name":"Data Research, Samil Pharm Co., Ltd.","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongwoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Data Research, Samil Pharm Co., Ltd.","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital","place":["Seongnam, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41433-024-03050-z","article-title":"Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020","volume":"38","author":"Furtado","year":"2024","journal-title":"Eye"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.3346\/jkms.2025.40.e128","article-title":"10-year change and projection in prevalence and incidence of exudative age-related macular degeneration in Korea","volume":"40","author":"Kim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2024.4401","article-title":"Economic burden of late-stage age-related macular degeneration in Bulgaria, Germany, and the US","volume":"142","author":"Paudel","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3341\/kjo.2016.0086","article-title":"Depressive symptoms and quality of life in age-related macular degeneration based on Korea National Health and Nutrition Examination Survey (KNHANES)","volume":"31","author":"Ryu","year":"2017","journal-title":"Korean J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1486168","DOI":"10.3389\/fpubh.2024.1486168","article-title":"Global, regional, and national burden of age-related macular degeneration, 1990\u20132019: an age-period-cohort analysis based on the Global Burden of Disease 2019 study","volume":"12","author":"Huang","year":"2024","journal-title":"Front Public Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.3346\/jkms.2025.40.e111","article-title":"Leveraging National Health Insurance Service data for public health research in Korea: structure, applications, and future directions","volume":"40","author":"Lim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.ophtha.2015.06.018","article-title":"Prevalence and incidence of exudative age-related macular degeneration in South Korea: a nationwide population-based study","volume":"122","author":"Park","year":"2015","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2023","journal-title":"Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e49852","DOI":"10.2196\/49852","article-title":"Patient-centered economic burden of exudative age-related macular degeneration: retrospective cohort study","volume":"9","author":"Choi","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1186\/s12913-019-4666-0","article-title":"Incremental economic burden associated with exudative age-related macular degeneration: a population-based study","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2531366","DOI":"10.1001\/jamanetworkopen.2025.31366","article-title":"Antithrombotic medications and intraocular hemorrhage risk in exudative age-related macular degeneration","volume":"8","author":"Kim","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/IAE.0b013e3181e2266d","article-title":"Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration","volume":"30","author":"Kiernan","year":"2010","journal-title":"Retina"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3341\/kjo.2024.0032","article-title":"Predictive factors for submacular hemorrhage in age-related macular degeneration: a retrospective study","volume":"38","author":"Moon","year":"2024","journal-title":"Korean J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.21561\/jor.2021.6.2.155","article-title":"Development of subretinal hemorrhage during treatment of neovascular age-related macular degeneration using a treat-and-extend regimen: a case report","volume":"6","author":"Kim","year":"2021","journal-title":"J Retina"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1741-7015-4-7","article-title":"Revision of visual impairment definitions in the international statistical classification of diseases","volume":"4","author":"Dandona","year":"2006","journal-title":"BMC Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:25:55Z","timestamp":1772688355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1766076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1766076"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1766076","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1766076"}}